NEWS Philips partners with Oxford University
Hospitals in digital pathology Royal Philips and Oxford University Hospitals (OUH) NHS Foundation Trust, have announced plans to create a digital pathology network to help drive faster and more efficient diagnoses for patients.
OUH will deploy the Philips IntelliSite
Pathology Solution at the John Radcliffe Hospital in Oxford, which will serve as a central laboratory service for partner sites at Milton Keynes University Hospital NHS Foundation Trust and Great Western Hospital NHS Foundation Trust in Swindon. Pathologists play a critical role in disease
detection, particularly with cancer diagnosis. Traditionally, pathologists analyse tissue samples on glass slides under a microscope. When seeking a consultation with a sub-specialist, these glass slides must be transported to the second site, which can result in lost or damaged slides or delays in diagnosis. By creating a digital network, OUH will leverage the pathology system, including its scanner and image management system, to allow clinicians across the three regions and within the Thames Valley Cancer Network to collaborate remotely on patient cases.
The aim of the collaboration is to help reduce delays in slide transport times, encourage more efficient workflows across the sites, and enable quicker access to specialist pathology opinions. Digital pathology will also support NHS
Surge in patients accessing clinical research
Improvement’s proposed Pathology networks, bringing together clinical expertise with the goal of enhancing patient outcomes. “As an NHS Global Digital Exemplar committed to improving patient care by embracing the latest digital technologies and cross-site collaborations, this partnership aims to modernise patient care and offer innovative world-leading services,” said Professor Clare Verrill, honorary consultant in cellular pathology at Oxford University Hospitals. “Initially starting with some specialist areas, we hope to soon make our pathology services fully digital, meaning our laboratory teams can maximise efficiency and focus on analysing samples rather than spending time manually transporting slides between hospitals.” Clinical cases will commence once network installation has completed, expected in Q3 2018.
Artificial heart transplant
leads to donor eligibility The National Research Center for Cardiac Surgery in Kazakhstan has confirmed the successful transplant of a donor heart in the first international patient implanted with the CARMAT heart in October 2017. CARMAT, a designer and developer of an advanced artificial heart project, aims to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure.
The surgery, consisting of the explant of the CARMAT bioprosthesis, followed by the transplant of a heart graft, was successfully performed by a team headed by Dr Yuriy Pya, CEO of the National Research Center for Cardiac Surgery, following eight months of support provided by the CARMAT total artificial heart (TAH).
The end stage heart failure patient was initially not eligible for a heart transplant as he suffered from pulmonary hypertension. The implant of the CARMAT device was performed in October 2017 as a bridge to transplant within the framework of the Pivotal study.
The patient’s health condition improved considerably during the eight month period
due to the support of the CARMAT device, allowing the patient to efficiently recover from pulmonary hypertension, become eligible for transplantation, and ultimately successfully receive a donor heart in June. The primary objective of the Pivotal study was largely met for this patient, as the study protocol calls for a 180-day (six months) post-implant survival or a successful heart transplantation replacing the device, within the 180-day timeframe. Dr. Yuriy Pya, CEO of the National
Research Center for Cardiac Surgery, said: “This patient, who was not initially eligible for a heart transplant due to pre-existing pulmonary hypertension, was supported by the CARMAT TAH for eight months. During this time, our team was able to monitor the improvement of the pulmonary hypertension assisted by the hemodynamic data which are continuously provided by the CARMAT TAH. The patient was in excellent condition before the transplant procedure and was only on light anticoagulant medication. The explant of the device left a natural space for the donor heart, which was then implanted according to our standard procedure.”
10 I
WWW.CLINICALSERVICESJOURNAL.COM
More patients than ever before have been given access to cutting-edge clinical research at Sheffield Teaching Hospitals NHS Foundation Trust, according to new national figures. The Trust saw a huge increase in the number of patients taking part in groundbreaking research, with 14,484 people taking part in clinical research studies run by the Trust in 2017 and 2018 compared to 11,490 between 2016 and 2017.
The figures, published by the National Institute for Health Research, place the Trust as the ninth highest performing research- active NHS Trust in the country. The 26% increase in numbers of patients accessing cutting-edge research saw the Trust ranked as 10th
for the
strongest increase in recruitment to research studies, with an extra 2994 patients taking part in research at the Trust’s five adult hospitals in 2017 and 2018 compared to the previous period.
Clinical research plays a vital role in improving care for patients, providing doctors and scientists with the evidence they need to better understand how diseases work, and paving the way for new drugs and technologies to be introduced into the clinic on routine basis. Professor Simon Heller, director of research and development at Sheffield Teaching Hospitals NHS Foundation Trust, attributed the large increase to a number of large research studies spanning across a wide range of medical specialities. This included an online study asking people to give their views on how managing and living with diabetes affects the quality of their lives, a study looking at the impact of the introduction of the minimum pricing of alcohol on alcohol-related attendances to emergency departments and sexual health clinics and a study measuring blood markers and genetic changes that may influence stroke and to help understand different types of stroke. “We are delighted to have given more patients than ever before access to ground- breaking clinical research. Using social media, we were able to recruit over 3000 patients to a large online diabetes study.”
Correction
The article in CSJ Volume 17, issue 7 incorrectly referenced The Leadership in Endoscopy Decontamination conference. The organiser was iM Med. CSJ apologises for this error.
SEPTEMBER 2018
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
